Diterpenoid component in hyssopus officinalis as well as separation and extraction method and application of diterpenoid component

Abstract

The invention relates to the technical field of hyssopus officinalis extracts and separation and purification, in particular to diterpenoid components in hyssopus officinalis as well as a separation and extraction method and application of the diterpenoid components in the hyssopus officinalis, and the diterpenoid components in the hyssopus officinalis are obtained according to the following method: extracting the hyssopus officinalis to obtain hyssopus officinalis total extract, extracting by using petroleum ether, filtering, and drying to obtain the diterpenoid components in the hyssopus officinalis. The preparation method comprises the following steps: taking hyssopus officinalis as a raw material, carrying out gradient elution separation for multiple times by silica gel column chromatography, and finally carrying out gradient elution purification separation by high performance liquid chromatography to obtain the diterpenoid component in the hyssopus officinalis, namely hyssopusone D. The invention discloses the compound hyssopusone D for the first time, the compound is subjected to an in-vitro anti-inflammatory pharmacodynamic experiment, and the experiment result obviously shows that the compound has a relatively strong inhibition effect on RAW 264.7 cells, so that the compound can be applied to preparation of medicines for preventing inflammation or / and resisting inflammation.

Description

Technical Field

[0001] The invention relates to the technical field of hyssopus officinalis extract and separation and purification, in particular to a diterpenoid component in hyssopus officinalis and a separation and extraction method thereof, and also relates to the application of the diterpenoid component in hyssopus officinalis in preparing drugs for preventing inflammation or / and resisting inflammation. Background Art

[0002] Hyssopus cuspidatus is a plant of the genus Hyssopus in the family Labiatae. The whole plant is used as medicine, with a faint fragrance, light taste, and slightly moist nature. It enters the lung and liver meridians, and has the effects of relieving cough and asthma, clearing heat and removing dampness. It is clinically used to treat tracheal inflammation, cough and asthma, colds and fever, and urinary problems. In addition, Hyssopus cuspidatus has the characteristics of easy source, low cost, reliable clinical efficacy, and small toxic and side effects. So far, there are few key and basic theoretical studies on Hyssopus cuspidatus. Modern pharmacology shows that its extract has significant anti-inflammatory and antibacterial activity, but no relevant research has been conducted on the chemical components. Hyssopus cuspidatus may be a very good species for treating respiratory diseases.

[0003] Therefore, it has attracted much attention in recent years.

[0004] The Chinese patent application document with publication number CN114044734A discloses a nepetabrate diterpene and its preparation method and application, discloses a compound (nepetabrate D) for the first time, and conducts an in vitro anti-inflammatory pharmacodynamics experiment on the compound. The experiment clearly shows that the compound has a strong inhibitory effect on RAW 264.7 cells, Staphylococcus aureus and Escherichia coli, so that the compound can be used as a preparation of anti-inflammatory and antibacterial drugs or / and anti-inflammatory and antibacterial drugs or / and preparation of anti-inflammatory and antibacterial health products.

[0005] The Chinese patent application document with publication number CN115708840A discloses the use of a Hyssop extract in the preparation of anti-lung cancer drugs. The Hyssop extract provided can significantly inhibit the proliferation, migration and invasion of human lung cancer cells A549 and NCI-H1975, affect the cell morphology and the release of inflammatory factors TNF-α and IL-6 in the cell supernatant, and has a dose-dependent effect, and effectively inhibits the secretion of matrix metalloenzymes MMP-2 and MMP-9 related to its invasion. Through the observation of pathological sections of the Lewis lung cancer in situ model of mice, Hyssop extract can reduce the number of tumor cells in Lewis lung cancer mice, significantly increase the concentration levels of IL-2 and IFN-γ in mouse serum, and effectively enhance the proliferation ability of lymphocytes and the number of NK cells in the spleen to regulate the immune function of Lewis lung cancer mice. At the same time, combined with cisplatin, it can reduce the immunosuppressive effect of cisplatin on lung cancer mice.

[0006] The medicinal effects of Hyssopus officinalis mainly come from the terpenoid compounds, including monoterpenoids and diterpenoids. Among them, the dominant component, diterpenoids, has good anti-inflammatory and antibacterial activities. Therefore, it is of great significance to develop and utilize the diterpenoid monomer compounds of Hyssopus officinalis, further explore its potential medicinal value, and determine and characterize the structure and physicochemical properties of its monomer compounds for the development and utilization of Hyssopus officinalis. Summary of the invention

[0007] The present invention provides a diterpenoid component in Hyssopus officinalis and a separation and extraction method and application thereof. The present invention discloses for the first time a diterpenoid component in Hyssopus officinalis (i.e., hyssopusone D) and discloses for the first time the application of hyssopusone D in the preparation of anti-inflammatory and / or anti-inflammatory or antibacterial drugs.

[0008] One of the technical solutions of the present invention is achieved by the following measures: a diterpenoid component in Hyssopus officinalis (i.e., hyssopusone D) has a chemical structural formula of:

[0009]

[0010] The following is a further optimization and / or improvement of one of the above-mentioned technical solutions:

[0011] The chemical name of the above hyssopusone D is (1S, 2R, 5S)-2-hydroxy-2-(2-(1R, 2S, 5R)-2-hydroxy-6,6-dimethyl-3-oxobicyclo[3.1.1]heptane-2-yl)ethyl)-6,6-dimethylbicyclo[3.1.1]heptan-3-one.

[0012] The English name of hyssopusone D is:

[0013] (1S,2R,5S)-2-hydroxy-2-(2-((1R,2S,5R)-2-hydroxy-6,6-dimethyl-3-oxobicyclo[3.1.1]heptan-2-yl)ethyl)-6,6-dimethylbicyclo[3.1.1]heptan-3-one.

[0014] The diterpenoid components in the above Hyssopus officinalis are prepared according to the following steps:

[0015] The first step is to crush the hard-pointed Hyssopus officinalis and add ethanol, soak at room temperature, heat and reflux extract at 40° C. to 60° C. for at least 2 times, each extraction time is 1 hour to 3 hours, combine each reflux extract, recover under reduced pressure, and concentrate to obtain the hard-pointed Hyssopus officinalis total extract;

[0016] The second step is to dissolve the total extract of Hyssopus officinalis in water and extract it with petroleum ether to obtain the petroleum ether extract;

[0017] The third step is to obtain 8 fractions after separation of the petroleum ether extract by silica gel column chromatography gradient elution, wherein the silica gel column chromatography gradient eluent includes petroleum ether and ethyl acetate, and the volume ratio of petroleum ether to ethyl acetate is 1:0, 100:1, 50:1, 25:1, 8:1, 5:1, 1:1, and 1:0, respectively;

[0018] In the fourth step, the sixth fraction of the eight fractions is subjected to gradient elution separation on a silica gel column chromatography to obtain five fractions, wherein the gradient eluent of the silica gel column chromatography comprises petroleum ether and ethyl acetate, and the volume ratios of petroleum ether to ethyl acetate are 20:1, 10:1, 3:1, 1:1, and 0:1, respectively;

[0019] The fifth step is to separate the third fraction of the five fractions obtained by silica gel column chromatography by gradient elution to obtain three fractions, wherein the silica gel column chromatography gradient eluent comprises petroleum ether and ethyl acetate, and the volume ratio of petroleum ether to ethyl acetate is 10:1, 5:1, and 3:1, respectively;

[0020] In the sixth step, the third fraction of the three fractions obtained is purified and separated by high performance liquid chromatography gradient elution, and the eluate is collected. The eluate collected at 27.0 minutes is the diterpenoid components in Hyssopus officinalis.

[0021] In the first step above, 8 to 10 ml of ethanol are added per 1 g of hard-tipped Hyssopus officinalis.

[0022] In the first step above, the soaking time is 3 to 4 hours.

[0023] In the first step above, the heating reflux extraction is performed three times.

[0024] In the sixth step, the eluent for the HPLC gradient elution is a mixture of methanol and water, wherein the volume ratio of methanol to water is 85:15.

[0025] The second technical solution of the present invention is achieved by the following measures: A method for separating and extracting diterpenoid components in Hyssopus officinalis is carried out according to the following steps:

[0026] The first step is to crush the hard-pointed Hyssopus officinalis and add ethanol, soak at room temperature, heat and reflux extract at 40° C. to 60° C. for at least 2 times, each extraction time is 1 hour to 3 hours, combine each reflux extract, recover under reduced pressure, and concentrate to obtain the hard-pointed Hyssopus officinalis total extract;

[0027] The second step is to dissolve the total extract of Hyssopus officinalis in water and extract it with petroleum ether to obtain the petroleum ether extract;

[0028] The third step is to obtain 8 fractions after separation of the petroleum ether extract by silica gel column chromatography gradient elution, wherein the silica gel column chromatography gradient eluent includes petroleum ether and ethyl acetate, and the volume ratio of petroleum ether to ethyl acetate is 1:0, 100:1, 50:1, 25:1, 8:1, 5:1, 1:1, and 1:0, respectively;

[0029] In the fourth step, the sixth fraction of the eight fractions is subjected to gradient elution separation on a silica gel column chromatography to obtain five fractions, wherein the gradient eluent of the silica gel column chromatography comprises petroleum ether and ethyl acetate, and the volume ratios of petroleum ether to ethyl acetate are 20:1, 10:1, 3:1, 1:1, and 0:1, respectively;

[0030] The fifth step is to separate the third fraction of the five fractions obtained by silica gel column chromatography by gradient elution to obtain three fractions, wherein the silica gel column chromatography gradient eluent comprises petroleum ether and ethyl acetate, and the volume ratio of petroleum ether to ethyl acetate is 10:1, 5:1, and 3:1, respectively;

[0031] In the sixth step, the third fraction of the three fractions obtained is purified and separated by high performance liquid chromatography gradient elution, and the eluate is collected. The eluate collected at 27.0 minutes is the diterpenoid components in Hyssopus officinalis.

[0032] The following is a further optimization and / or improvement of the second technical solution of the above invention:

[0033] In the first step above, 8 to 10 ml of ethanol are added per 1 g of hard-tipped Hyssopus officinalis.

[0034] In the first step above, the soaking time is 3 to 4 hours.

[0035] In the first step above, the heating reflux extraction is performed three times.

[0036] In the sixth step, the eluent for the HPLC gradient elution is a mixture of methanol and water, wherein the volume ratio of methanol to water is 85:15.

[0037] The third technical solution of the present invention is achieved through the following measures: an application of diterpenoid components in Hyssopus officinalis in the preparation of drugs for preventing inflammation and / or anti-inflammatory drugs.

[0038] The following is a further optimization and / or improvement of the third technical solution of the above invention:

[0039] The above-mentioned anti-inflammatory drug refers to a drug for preventing RAW 264.7 cell inflammation.

[0040] The above-mentioned anti-inflammatory drugs refer to anti-RAW 264.7 cell inflammation anti-inflammatory drugs.

[0041] The present invention discloses the compound hyssopusone D for the first time, and conducts an in vitro anti-inflammatory pharmacodynamics experiment on the compound. According to the experimental results, it can be clearly seen that the compound has a strong inhibitory effect on RAW 264.7 cells, so that the compound can be used as a drug for preparing inflammation prevention and / or anti-inflammatory drugs. BRIEF DESCRIPTION OF THE DRAWINGS

[0042] Attached Figure 1 The figure is the chemical structure diagram of hyssopusone D described in the present invention.

[0043] Attached Figure 2 The hyssopusone D of the present invention 1 H-NMR spectrum.

[0044] Attached Figure 3 The hyssopusone D of the present invention 13 C-APT spectrum. DETAILED DESCRIPTION

[0045] The present invention is not limited by the following embodiments, and specific implementation methods can be determined based on the technical solution of the present invention and actual conditions.

[0046] Unless otherwise specified, the various chemical reagents and chemicals mentioned in the present invention are all chemical reagents and chemicals commonly known in the prior art; the percentages in the present invention are all mass percentages unless otherwise specified; the solutions in the present invention are all aqueous solutions with water as the solvent unless otherwise specified, for example, hydrochloric acid solution is an aqueous hydrochloric acid solution; the normal temperature and room temperature in the present invention generally refer to a temperature of 15°C to 25°C, and are generally defined as 25°C.

[0047] The present invention will be further described below in conjunction with embodiments:

[0048] Example 1: A diterpenoid component from Hyssopus officinalis, namely hyssopusone D, has the chemical structural formula:

[0049]

[0050] The chemical name of hyssopusone D is (1S, 2R, 5S)-2-hydroxy-2-(2-(1R, 2S, 5R)-2-hydroxy-6,6-dimethyl-3-oxobicyclo[3.1.1]heptane-2-yl)ethyl)-6,6-dimethylbicyclo[3.1.1]heptan-3-one.

[0051] The English name of hyssopusone D is:

[0052] (1S,2R,5S)-2-hydroxy-2-(2-((1R,2S,5R)-2-hydroxy-6,6-dimethyl-3-oxobicyclo[3.1.1]heptan-2-yl)ethyl)-6,6-dimethylbicyclo[3.1.1]heptan-3-one.

[0053] Example 2, as an optimization of the above example, the diterpenoid components in Hyssopus officinalis were prepared according to the following steps:

[0054] The first step is to crush the hard-pointed Hyssopus officinalis and add ethanol, soak at room temperature, heat and reflux extract at 40° C. to 60° C. for at least 2 times, each extraction time is 1 hour to 3 hours, combine each reflux extract, recover under reduced pressure, and concentrate to obtain the hard-pointed Hyssopus officinalis total extract;

[0055] The second step is to dissolve the total extract of Hyssopus officinalis in water and extract it with petroleum ether to obtain the petroleum ether extract;

[0056] The third step is to obtain 8 fractions after separation of the petroleum ether extract by silica gel column chromatography gradient elution, wherein the silica gel column chromatography gradient eluent includes petroleum ether and ethyl acetate, and the volume ratio of petroleum ether to ethyl acetate is 1:0, 100:1, 50:1, 25:1, 8:1, 5:1, 1:1, and 1:0, respectively;

[0057] In the fourth step, the sixth fraction of the eight fractions is subjected to gradient elution separation on a silica gel column chromatography to obtain five fractions, wherein the gradient eluent of the silica gel column chromatography comprises petroleum ether and ethyl acetate, and the volume ratios of petroleum ether to ethyl acetate are 20:1, 10:1, 3:1, 1:1, and 0:1, respectively;

[0058] The fifth step is to separate the third fraction of the five fractions obtained by silica gel column chromatography by gradient elution to obtain three fractions, wherein the silica gel column chromatography gradient eluent comprises petroleum ether and ethyl acetate, and the volume ratio of petroleum ether to ethyl acetate is 10:1, 5:1, and 3:1, respectively;

[0059] In the sixth step, the third fraction of the three fractions obtained is purified and separated by high performance liquid chromatography gradient elution, and the eluate is collected. The eluate collected at 27.0 minutes is the diterpenoid components in Hyssopus officinalis.

[0060] Example 3, as an optimization of the above Example 2, in the first step, 8 ml to 10 ml of ethanol is added to every 1 g of hard-tipped Hyssopus officinalis.

[0061] Example 4, as an optimization of the above Example 2, in the first step, the soaking time is 3 hours to 4 hours.

[0062] Example 5, as an optimization of the above Example 2, in the first step, the number of heating reflux extraction is 3 times.

[0063] Example 6, as an optimization of the above-mentioned Example 2, in the sixth step, the eluent for the HPLC gradient elution is a mixture of methanol and water, wherein the volume ratio of methanol to water is 85:15.

[0064] Example 7, use of the diterpenoid components in Hyssopus officinalis in the preparation of drugs for preventing inflammation and / or resisting inflammation.

[0065] Example 8, as an optimization of the above Example 7, the drug for preventing inflammation refers to a drug for preventing RAW 264.7 cell inflammation.

[0066] Example 9, as an optimization of the above Example 7, the anti-inflammatory drug refers to an anti-inflammatory drug against RAW 264.7 cell inflammation.

[0067] Example 10: The diterpenoid components in Hyssopus officinalis were prepared according to the following steps:

[0068] The first step is to crush the hard-pointed Hyssopus officinalis and add ethanol, adding 8 ml to 10 ml of ethanol to every 1 gram of the hard-pointed Hyssopus officinalis, soaking at room temperature for 3 to 4 hours, heating and refluxing extraction at 40° C. to 60° C. for 3 times, each extraction time being 1 to 3 hours, combining each reflux extract, recovering under reduced pressure, and concentrating to obtain the hard-pointed Hyssopus officinalis total extract;

[0069] The second step is to dissolve the total extract of Hyssopus officinalis in water and extract it with petroleum ether to obtain the petroleum ether extract;

[0070] The third step is to obtain 8 fractions after separation of the petroleum ether extract by silica gel column chromatography gradient elution, wherein the silica gel column chromatography gradient eluent includes petroleum ether and ethyl acetate, and the volume ratio of petroleum ether to ethyl acetate is 1:0, 100:1, 50:1, 25:1, 8:1, 5:1, 1:1, and 1:0, respectively;

[0071] In the fourth step, the sixth fraction of the eight fractions is subjected to gradient elution separation on a silica gel column chromatography to obtain five fractions, wherein the gradient eluent of the silica gel column chromatography comprises petroleum ether and ethyl acetate, and the volume ratios of petroleum ether to ethyl acetate are 20:1, 10:1, 3:1, 1:1, and 0:1, respectively;

[0072] The fifth step is to separate the third fraction of the five fractions obtained by silica gel column chromatography by gradient elution to obtain three fractions, wherein the silica gel column chromatography gradient eluent comprises petroleum ether and ethyl acetate, and the volume ratio of petroleum ether to ethyl acetate is 10:1, 5:1, and 3:1, respectively;

[0073] In the sixth step, the third fraction of the three fractions obtained is purified and separated by HPLC gradient elution, and the eluate is collected. The eluate collected at 27.0 minutes is the diterpenoid components in Hyssopus officinalis, wherein the eluent of the HPLC gradient elution is a mixture of methanol and water, and the volume ratio of methanol to water is 85:15.

[0074] The diterpenoid component (hyssopusone D) in the Hyssopus officinalis obtained in Example 10 was analyzed by nuclear magnetic resonance hydrogen spectrum (1H-NMR) and nuclear magnetic resonance carbon spectrum (13C-APT).

[0075] The 1H-NMR spectrum of hyssopusone D described in Example 10 is as follows Figure 2 shown.

[0076] The 13C-APT spectrum of the hyssopusone D described in Example 10 is as follows Figure 3 shown.

[0077] right Figure 2 and Figure 3 Perform graph analysis and Figure 2 and Figure 3 The peaks were assigned to obtain the chemical shifts and peak types of carbon and hydrogen in the structure of the compound hyssopusone D. Its chemical structure is as follows Figure 1 As shown. Among them, Figure 2 and Figure 3 The peaks are listed in Table 1.

[0078] In vitro anti-inflammatory pharmacodynamics experiment of the diterpenoid component (hyssopusone D) in the Hyssopus officinalis of the present invention:

[0079] The hyssopusone D obtained in Example 10 of the present invention was subjected to an in vitro anti-inflammatory pharmacodynamics experiment using the MTT colorimetric method.

[0080] Hyssopusone D was used as the experimental group, Aspinin (aspirin, an anti-inflammatory drug) was used as the control group, and a blank group was set up. RAW 264.7 cells were selected as the experimental objects in the experimental group, the control group and the blank group. After the culture medium was diluted, 6×10 4 / ml density was inoculated in 96-well plates, 100μl per well, and after normal culture in the incubator for 24 hours, the corresponding drugs were added to each group, so that the final concentrations of the drugs in each group were 2.5μg / ml (group 1), 5μg / ml (group 2), 10μg / ml (group 3), 20μg / ml (group 4), and 40μg / ml (group 5), respectively. There were 5 concentrations in total, and 3 replicates for each concentration; after culture for 48 hours, 10μl of MTT was added to each well for staining; after further culture for four hours, the original culture medium was aspirated and discarded, 150μl of DMSO was added to each well, and the wells were shaken at a low speed on a shaker for 10 minutes to fully dissolve the crystals, and the optical density value was detected at a wavelength of 570nm using an enzyme-linked immunosorbent assay, and the 50% inhibition concentration (IC) was calculated based on the optical density value. 50 , μM), and IC was calculated using optical density values 50 The calculation method of IC of RAW 264.7 cells in the experimental group and the control group 50 As shown in Table 2.

[0081] It can be seen from the data in Table 2 that hyssopusone D of the present invention has a certain inhibitory effect on RAW 264.7 cells.

[0082] In summary, the present invention discloses the compound hyssopusone D for the first time, and conducts an in vitro anti-inflammatory pharmacodynamics experiment on the compound. The experiment clearly shows that the compound has a strong inhibitory effect on RAW 264.7 cells, so that the compound can be used as a drug for the preparation of anti-inflammatory and / or anti-inflammatory and antibacterial drugs.

[0083] The above technical features respectively constitute various embodiments of the present invention, which have strong adaptability and implementation effect. Non-essential technical features can be added or reduced according to actual needs to meet the requirements of different situations.

[0084] Table 1

[0085]

[0086]

[0087] Table 2

[0088] Compound <![CDATA[IC 50 (μM)]]> Aspinin 0.36±1.22 hyssopusoneD 25.7±0.1

Claims

1. A diterpenoid component in Hyssopus officinalis, characterized in that: Its chemical structure is:

2. The diterpenoid component in Hyssopus officinalis according to claim 1, characterized in that: The chemical name is (1S, 2R, 5S)-2-hydroxy-2-(2-(1R, 2S, 5R)-2-hydroxy-6,6-dimethyl-3-oxobicyclo[ 3.1.1]heptane-2-yl)ethyl)-6,6-dimethylbicyclo[3.1.1]heptan-3-one.

3. The diterpenoid component in Hyssopus officinalis according to claim 1 or 2, characterized in that: Prepared according to the following steps: The first step is to crush the hard-pointed Hyssopus officinalis and add ethanol, soak at room temperature, heat and reflux extract at 40° C. to 60° C. for at least 2 times, each extraction time is 1 hour to 3 hours, combine each reflux extract, recover under reduced pressure, and concentrate to obtain the hard-pointed Hyssopus officinalis total extract; The second step is to dissolve the total extract of Hyssopus officinalis in water and extract it with petroleum ether to obtain the petroleum ether extract; The third step is to obtain 8 fractions after separation of the petroleum ether extract by silica gel column chromatography gradient elution, wherein the silica gel column chromatography gradient eluent includes petroleum ether and ethyl acetate, and the volume ratio of petroleum ether to ethyl acetate is 1:0, 100:1, 50:1, 25:1, 8:1, 5:1, 1:1, and 1:0, respectively; In the fourth step, the sixth fraction of the eight fractions is subjected to gradient elution separation on a silica gel column chromatography to obtain five fractions, wherein the gradient eluent of the silica gel column chromatography comprises petroleum ether and ethyl acetate, and the volume ratios of petroleum ether to ethyl acetate are 20:1, 10:1, 3:1, 1:1, and 0:1, respectively; The fifth step is to separate the third fraction of the five fractions obtained by silica gel column chromatography by gradient elution to obtain three fractions, wherein the silica gel column chromatography gradient eluent comprises petroleum ether and ethyl acetate, and the volume ratio of petroleum ether to ethyl acetate is 10:1, 5:1, and 3:1, respectively; In the sixth step, the third fraction of the three fractions obtained is purified and separated by high performance liquid chromatography gradient elution, and the eluate is collected. The eluate collected at 27.0 minutes is the diterpenoid components in Hyssopus officinalis.

4. The diterpenoid component in Hyssopus officinalis according to claim 3, characterized in that In the first step, 8 ml to 10 ml of ethanol are added per 1 g of hard-tipped Hyssopus officinalis.

5. The diterpenoid component in Hyssopus officinalis according to claim 3 or 4, characterized in that: In the first step, the soaking time is 3 hours to 4 hours; or / and, in the first step, the heating reflux extraction is performed 3 times.

6. The diterpenoid component in Hyssopus officinalis according to claim 3 or 5, characterized in that: In the sixth step, the eluent for the HPLC gradient elution is a mixture of methanol and water, wherein the volume ratio of methanol to water is 85:

15.

7. The diterpenoid component in Hyssopus officinalis according to claim 4, characterized in that: In the sixth step, the eluent for the HPLC gradient elution is a mixture of methanol and water, wherein the volume ratio of methanol to water is 85:

15.

8. A method for separating and extracting diterpenoid components from Hyssopus officinalis according to claim 1, 2, 4, 5, 6 or 7, characterized in that: Follow the steps below: The first step is to crush the hard-pointed Hyssopus officinalis and add ethanol, soak at room temperature, heat and reflux extract at 40° C. to 60° C. for at least 2 times, each extraction time is 1 hour to 3 hours, combine each reflux extract, recover under reduced pressure, and concentrate to obtain the hard-pointed Hyssopus officinalis total extract; The second step is to dissolve the total extract of Hyssopus officinalis in water and extract it with petroleum ether to obtain the petroleum ether extract; The third step is to obtain 8 fractions after separation of the petroleum ether extract by silica gel column chromatography gradient elution, wherein the silica gel column chromatography gradient eluent includes petroleum ether and ethyl acetate, and the volume ratio of petroleum ether to ethyl acetate is 1:0, 100:1, 50:1, 25:1, 8:1, 5:1, 1:1, and 1:0, respectively; In the fourth step, the sixth fraction of the eight fractions is subjected to gradient elution separation on a silica gel column chromatography to obtain five fractions, wherein the gradient eluent of the silica gel column chromatography comprises petroleum ether and ethyl acetate, and the volume ratios of petroleum ether to ethyl acetate are 20:1, 10:1, 3:1, 1:1, and 0:1, respectively; The fifth step is to separate the third fraction of the five fractions obtained by silica gel column chromatography by gradient elution to obtain three fractions, wherein the silica gel column chromatography gradient eluent comprises petroleum ether and ethyl acetate, and the volume ratio of petroleum ether to ethyl acetate is 10:1, 5:1, and 3:1, respectively; In the sixth step, the third fraction of the three fractions obtained is purified and separated by high performance liquid chromatography gradient elution, and the eluate is collected. The eluate collected at 27.0 minutes is the diterpenoid components in Hyssopus officinalis.

9. Use of the diterpenoid component in Hyssopus officinalis according to any one of claims 1 to 7 in the preparation of drugs for preventing inflammation and / or resisting inflammation.

10. The use of the diterpenoid components in Hyssopus officinalis according to claim 9 in the preparation of drugs for preventing inflammation or / and resisting inflammation, characterized in that: The anti-inflammatory drug refers to a drug that prevents RAW 264.7 cell inflammation; or / and, the anti-inflammatory drug refers to an anti-inflammatory drug that resists RAW 264.7 cell inflammation.

Images